Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial

The Lancet Infectious Diseases · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles